Back | Next |
home / stock / apto / apto message board
Subject | By | Source | When |
---|---|---|---|
Possible reason for Zilo phase 3 trial termination? | dcaf7 | investorshub | 04/07/2023 1:22:22 PM |
Seems like a saga with naked ant-ROR1 antibody | dcaf7 | investorshub | 04/06/2023 10:48:14 PM |
One additional risk shareholders have here is the | Zeppo | investorshub | 04/06/2023 6:41:07 PM |
Most of the market and analyst reports are | Tartiaboy | investorshub | 04/05/2023 3:35:56 PM |
Top 3 Canadian Pharma Stocks of 2023. | dcaf7 | investorshub | 04/05/2023 1:13:18 PM |
They should execute on their own guidance. It | dcaf7 | investorshub | 03/31/2023 10:06:39 PM |
If they are not slow walking Lux, what | Wolverine3 | investorshub | 03/31/2023 7:46:56 PM |
I'm more interested in them getting to the | Tartiaboy | investorshub | 03/31/2023 5:09:39 PM |
In January Corporate presentation you can find, 1Q | dcaf7 | investorshub | 03/29/2023 5:08:22 PM |
I think it will depend on how strong | Tartiaboy | investorshub | 03/29/2023 4:37:34 PM |
ADMIRAL trial was Gilteritinib against salvage therapy in | dcaf7 | investorshub | 03/29/2023 4:30:52 PM |
In the case of TUSP monotherapy I am | Tartiaboy | investorshub | 03/28/2023 3:01:49 PM |
Im going to start praying to St. Jude, | spiderman3600 | investorshub | 03/28/2023 12:28:40 PM |
Would do cartwheels for $8/share | Wolverine3 | investorshub | 03/28/2023 12:54:34 AM |
Canaccord Genuity has decided to maintain its Buy | dcaf7 | investorshub | 03/27/2023 9:06:53 PM |
It should affect Aptose. After that, don't think | dcaf7 | investorshub | 03/25/2023 1:34:23 PM |
That's my point. The design and targets | Tartiaboy | investorshub | 03/24/2023 5:59:48 PM |
Yes, unless they want to recruit Ven-naive patients. | dcaf7 | investorshub | 03/24/2023 5:21:45 PM |
Getting a first look at the population that | Tartiaboy | investorshub | 03/24/2023 4:42:45 PM |
As I previosly mentioned, Tusp/Ven trial won't be | dcaf7 | investorshub | 03/24/2023 4:21:37 PM |
News, Short Squeeze, Breakout and More Instantly...
Aptose Biosciences Inc. Company Name:
APTO Stock Symbol:
NASDAQ Market:
Aptose Biosciences Inc. Website:
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, t...
SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies,...
TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VEN Doublet Therapy Active in...